Trial Profile

Sickle Cell Disease Stem Cell Mobilization and Apheresis Using Motiixafortide

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Motixafortide (Primary)
Indications Sickle cell anaemia
Focus Adverse reactions
Acronyms SCDSTEMM

Most Recent Events

31 Mar 2025 According to a BioLineRx media release, the first patient dosed in the multi-center Phase 1 clinical trial.
10 Dec 2024 Trial design presented at the 66th American Society of Hematology Annual Meeting and Exposition
08 Nov 2024 Planned initiation date changed from 1 Nov 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com